Figure 2

Different uptake of [¹¹¹In]In-PSMA-617 between treated and untreated animals but not between animals co-injected with rA1M or not. SPECT images of the ¹¹¹In activity in animals convolved by a 2 mm FWHM Gauss filter, taken 7 h p.i. [¹¹¹In]In-PSMA-617 at 135 days post first ¹⁷⁷Lu injection. Maximum intensity projections using the “Hot” color scale windowed to best display kidneys with the top activity noted. Annotations: b = bladder and k = kidney. (A) Animal from the [¹⁷⁷Lu}Lu-PSMA-617 + rA1M group. (B) Animal from the [¹⁷⁷Lu}Lu-PSMA-617 + PBS group. Outlier in cycle 2. (C) Animal from the untreated control group. (D) Kidney accumulation (%IA/g) of [¹¹¹In]In-PSMA-617 at end of study 135 days post first injection. The [¹⁷⁷Lu]Lu-PSMA-617 + PBS group had higher mean and median accumulation than [¹⁷⁷Lu]Lu-PSMA-617 + rA1M, at both time points, the difference, however, was not statistically significant. Both PSMA groups had significantly higher accumulation than the untreated group using the Kruskal–Wallis test and the Bonferroni correction for multiple tests. ★ indicates values labelled as major outliers by the statistical analysis software SPSS. ***p < 0.001.